LL 37 vs Thymosin Alpha 1
Evidence tier, human-evidence strength, regulatory status, and hype-vs-data — side by side.
On published evidence, Thymosin Alpha 1 currently grades higher (C-tier vs F-tier). That reflects evidence maturity, not that it's “better” for any person or goal.
- Stronger human evidence: Thymosin Alpha 1
- More hype than data: neither stands out
| ll-37 | thymosin-alpha-1 | |
|---|---|---|
| Class | Thymic & immune-modulating peptides | Thymic & immune-modulating peptides |
| Regulatory status | Research-use-only | Investigational |
| Candidate sources | 0 | 0 |
| Top study types (candidate) | — | — |
| Translation risk | pending review | pending review |
LL 37 vs Thymosin Alpha 1: FAQ
Is LL 37 better than Thymosin Alpha 1?
On published evidence, Thymosin Alpha 1 currently grades higher (C-tier vs F-tier). That reflects evidence maturity, not that it's “better” for any person or goal. Neither is a recommendation to use anything; this compares the state of the evidence only.
What's the difference between LL 37 and Thymosin Alpha 1?
LL 37 is research-use-only and sits at the “Animal” evidence stage; Thymosin Alpha 1 is investigational and sits at “Clinical trials.”
Which has stronger human evidence, LL 37 or Thymosin Alpha 1?
Thymosin Alpha 1 has the stronger human-evidence signal of the two on our scale.
Research reference only. Not medical advice, treatment instructions, or a purchase recommendation. Consult a licensed professional.